目的:观察雷贝拉唑联合康复新液治疗Ⅱ、Ⅲ级反流性食管炎的临床疗效及安全性。方法:79例Ⅱ、Ⅲ级反流性食管炎患者随机分成两组,观察组40例给予雷贝拉唑胶囊10 mg,po bid,康复新液10 ml,po tid;对照组39例仅予雷贝拉唑胶囊10 mg,po bid治疗。疗程均为8周。观察两组患者的临床疗效、治疗前后临床症状评分、胃镜下食管炎改善情况及药品不良反应。结果:两组患者治疗后症状评分较治疗前明显下降(P<0.001),观察组下降较对照组更为明显(P<0.01);按临床症状疗效判定,观察组显效率明显高于对照组(P<0.05);按胃镜检查疗效判定,观察组显效率(P<0.01)及总有效率(P<0.05)均较对照组显著增高。两组不良反应少。结论:雷贝拉唑联合康复新液治疗Ⅱ、Ⅲ级反流性食管炎疗效优于单一使用雷贝拉唑,且安全性好。 Objective: To observe the clinical efficacy and safety of rabeprazole combined with Kangfuxin liquid in the treatment of grade Ⅱ and Ⅲ reflux esophagitis. Methods: A total of 79 patients with grade Ⅱ and Ⅲ reflux esophagitis were randomly divided into two groups. The observation group was treated with rabeprazole capsule 10 mg, po bid, Kangfuxin solution 10 ml, po tid, and the control group 39 cases only Rabeprazole capsule 10 mg, po bid treatment. The course of treatment is 8 weeks. To observe the clinical efficacy of two groups of patients, clinical symptoms before and after treatment, endoscopic esophagitis to improve the situation and adverse drug reactions. Results: After treatment, the scores of symptoms in both groups were significantly decreased (P <0.001), and the decrease in the observation group was more obvious than that in the control group (P <0.01). According to the clinical symptoms and curative effect, the apparent efficiency of the observation group was significantly higher than that of the control group (P <0.05). According to the results of gastroscopy examination, the markedly effective rate (P <0.01) and total effective rate (P <0.05) in the observation group were significantly higher than those in the control group. Two adverse reactions less. Conclusion: Rabeprazole combined with Kangfuxin solution is superior to rabeprazole alone in the treatment of grade Ⅱ and Ⅲ reflux esophagitis, and its safety is good.